Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid

BACKGROUND: Early and accurate detection and staging is critical to managing Alzheimer’s disease (AD) and supporting clinical trials. Cerebrospinal fluid (CSF) biomarkers for amyloid-β peptides, tau species, and various neurodegenerative and inflammatory analytes are leading the way in this regard,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Alzheimers Dis
Autors principals: Triana-Baltzer, Gallen, Van Kolen, Kristof, Theunis, Clara, Moughadam, Setareh, Slemmon, Randy, Mercken, Marc, Galpern, Wendy, Sun, Hong, Kolb, Hartmuth
Format: Artigo
Idioma:Inglês
Publicat: IOS Press 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683057/
https://ncbi.nlm.nih.gov/pubmed/32831201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-200463
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars